Amgen picks its moment to strike for Chemocentryx
The $3.7bn price is cheaper than it would have been last year, but Tavneos must still fulfill its pipeline-in-a-product potential.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.